Developer docs
API playgroundTry for free, no card

Search company profiles

Clairity

Full company profile

uuid0000c3b

Namestring
Clairity
Legal namestring
Clairity, Inc.
Websiteurl
clairity.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Clairity, Inc., founded in 2020 and headquartered at 361 Newbury Street, Boston, Massachusetts, develops an AI-powered precision health platform that converts routine screening mammograms into a personalized five-year risk score for breast cancer. Its flagship Software as a Medical Device, Clairity Breast (FDA-authorized under the device name Allix5 via De Novo in May 2025), applies proprietary deep-learning and pixel-level radiomics analysis to full-field digital mammograms and directly acquired 2D images from compatible systems such as Hologic Lorad Selenia/Selenia Dimensions. The model was trained on millions of mammograms with five-year outcome data and validated across more than 122,000 mammograms spanning ten U.S. health systems and European screening programs, achieving a clinical accuracy of AUC 0.72 and identifying a 2–4x higher risk in women missed by traditional density-based methods. Clairity Breast is the first AI mammography risk tool incorporated into the NCCN 2026 Clinical Practice Guidelines for Breast Cancer Screening and Diagnosis, with a 1.7% risk threshold and eligibility starting at age 35.

The platform is delivered to U.S. health systems, academic medical centers, and specialty breast imaging networks through an enterprise SaaS / risk-assessment software licensing model (quote-based, multi-year), embedded inside MagView's Luminary Risk workflow software that reaches 2,500+ U.S. imaging facilities, and combined with Myriad Genetics' MyRisk Hereditary Cancer Test via a co-developed AI + genetic risk offering launched in November 2025. Secondary revenue mechanics include a $40–$60 imaging-center add-on and a $199 direct self-pay option for individual risk scores; insurance coverage remains limited. Named deployments include Beth Israel Deaconess Medical Center (first commercial patient February 23, 2026), Emory University, and Invision Sally Jobe, with a state-by-state U.S. rollout underway (Massachusetts launched; Colorado scheduled April 2026). Clairity is led by founder/CEO Dr. Connie Lehman, with Joe Kiani (founder of Masimo) as Chairman, and has raised approximately $50 million in disclosed funding, most recently a $43 million Series B in November 2025 co-led by ACE Global Equity and Santé Ventures with participation from the Breast Cancer Research Foundation.

Short descriptiontext

Clairity provides Clairity Breast, an FDA-authorized AI platform that predicts a woman's five-year breast cancer risk directly from a routine screening mammogram. It serves U.S. health systems, academic medical centers, and breast imaging networks via enterprise SaaS, channel integrations, and direct-to-consumer access.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
medical imaging AI, breast cancer risk prediction, AI mammography software, precision health diagnostics, software as a medical device
Industry2 codes
PRIMARYHDAAAEAH
Medical Imaging AI
SECONDARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
NAICS code1 code
  • Computer Systems Design and Related Services54151
Product category
Medical Imaging AI Software / Precision Health Diagnostics
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Enterprise SaaS / risk-assessment software licensing to health systems and imaging centers
TypeSubscription Recurring
Description

Recurring software access deployed within clinical imaging workflows (e.g., integration with MagView's Luminary Risk used by 2,500+ U.S. facilities and with Myriad Genetics testing workflows). Billed to healthcare providers per the B2B health system contract model.

globenewswire.com
2Per-test / per-mammogram patient access fees (self-pay and imaging-center add-on)
TypeUsage Based
Description

Some imaging centers offer the AI analysis as an optional add-on for $40–$60; self-pay option priced at $199. Insurance coverage remains limited, indicating near-term revenue from out-of-pocket per-assessment transactions.

survivornet.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Others
Pricing details3 tiers
1Imaging center add-on (optional AI risk assessment at time of screening)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$40–$60 as an optional add-on at some centers.

survivornet.com
2Direct self-pay patient pricing
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$199 self-pay for individual risk-score access.

survivornet.com
3Enterprise health system pricing (quote-based)
ModelOtherBilling cadenceMulti-year contract
Notes

Not publicly disclosed; Quote-based / Not publicly disclosed for hospital-based and freestanding screening programs.

clairity.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1Clairity Breast
Description

First FDA-authorized AI platform that predicts a woman's five-year future risk of developing breast cancer using only her existing screening mammogram. Authorized under the name Allix5.

clairity.com
Core offering1 text field

Clairity develops and commercializes Clairity Breast (FDA-authorized under the device name Allix5), a Software as a Medical Device (SaMD) that applies deep learning and computer vision to full-field digital mammograms from Hologic Lorad Selenia / Selenia Dimensions systems to output a five-year probability of a woman developing breast cancer, without relying on family history or genetic inputs. The platform is sold primarily as enterprise SaaS/risk-assessment software licensed to U.S. health systems and imaging centers, integrated with MagView's Luminary Risk workflow and Myriad's MyRisk genetic testing, and is also offered as an imaging-center add-on ($40-$60) or self-pay ($199) for individual risk-score access.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 5.9% breast cancer incidence in AI high-risk women vs 1.3% in average-risk (validation studies)
+4 more records
Product overview1 text field

Clairity, Inc. offers a single unified product, Clairity Breast (FDA-authorized under the device name Allix5), an AI-powered Software as a Medical Device that analyzes routine screening mammograms to produce a personalized 5-year breast cancer risk score. The platform is extended through a workflow integration with MagView's Luminary Risk software that brings Clairity Breast's risk score together with Myriad Genetics' MyRisk Hereditary Cancer Test (with RiskScore) results, so radiologists can act on combined image-based and genetic risk inside their existing breast imaging workflow.

Product and service1 record
1Clairity Breast (FDA-authorized device name: Allix5)
CategoryMedical imaging AI / Software as a Medical Device (SaMD) — breast cancer risk prediction
Description

Clairity Breast is Clairity's flagship Software as a Medical Device (SaMD) that uses deep learning and computer vision to analyze full-field digital mammograms (or directly acquired 2D images from Hologic Lorad Selenia / Selenia Dimensions systems) and output a personalized five-year probability of a woman developing breast cancer, without relying on family history or genetic inputs. It is FDA De Novo-authorized under the device name Allix5, validated across 120,000+ mammograms from ten U.S. health systems and European screening programs (AUC 0.72), and is sold to U.S. health systems, academic medical centers, and specialty breast imaging networks with deployments at Beth Israel Deaconess Medical Center, Emory University, and Invision Sally Jobe.

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership14 partners
1Patient Safety Movement Foundation
Strategic tierIndustry Alliance ParticipationTypeOthersAnnounced on2026-03-30
Description

Clairity Inc. signed the Patient Safety Movement Foundation's Open Data Pledge (announced March 30, 2026), joining 90+ organizations committed to making clinical data accessible in secure ways to improve patient safety. The pledge enables appropriate access to data from medical technologies including EHRs, infusion pumps, and physiological monitors, supporting AI-driven predictive algorithms. Joe Kiani (Clairity Chairman) founded the Patient Safety Movement Foundation in 2012.

pharmiweb.com
Strategic tierFlagship Launch SiteTypeImplementation/ SI/ Consulting PartnerAnnounced on2026-02-23
Description

First medical center in the U.S. to offer Clairity Breast; the first clinical patient received a Clairity Breast cancer risk score on February 23, 2026, marking the clinical debut of the FDA-authorized platform.

3Clairity Strategic Advisory Board
Strategic tierStrategic AdvisoryTypeOthersAnnounced on2025-12-02
Description

Strategic Advisory Board formed December 2, 2025 to support deployment of Clairity's AI-based health prediction tools and the global rollout of its predictive AI technologies at scale. Includes leaders from diagnostics, digital health, and life sciences.

prnewswire.com
Strategic tierFlagship Commercial IntegrationTypeStrategic or Co-development PartnerAnnounced on2025-11-25
Description

Jointly developed and launched (Nov 25, 2025) the first integrated AI and genetic risk platform for personalized breast health, combining Clairity Breast (image-based AI) with Myriad's MyRisk Hereditary Cancer Test with RiskScore within MagView's Luminary Risk workflow software. Strategic collaboration also covers U.S. integrated breast cancer risk assessment.

Strategic tierFlagship Distribution ChannelTypeStrategic or Co-development PartnerAnnounced on2025-11-25
Description

Co-developed and distributed the first integrated AI + genetic risk platform for personalized breast health. MagView's Luminary Risk workflow software is used by more than 2,500 facilities across the United States, providing broad distribution for Clairity Breast alongside Myriad's MyRisk Hereditary Cancer Test.

Strategic tierFounding Clinical / Data PartnerTypeStrategic or Co-development Partner
Description

Founding data partner of Clairity's Data Partner Consortium, contributing clinical expertise, patient diversity, and data excellence for AI model development and validation. Founder Dr. Connie Lehman was a Breast Imaging Specialist at MGH (on leave).

Strategic tierFounding Research PartnerTypeStrategic or Co-development Partner
Description

Founding data partner and academic research collaborator. Founder Dr. Lehman has a documented research collaboration with MIT that helped fuel Clairity's founding.

Strategic tierData PartnerTypeStrategic or Co-development Partner
Description

Member of Clairity's founding Data Partner Consortium, contributing thought leadership, clinical expertise, and patient diversity.

Strategic tierData PartnerTypeStrategic or Co-development Partner
Description

Member of Clairity's founding Data Partner Consortium, contributing clinical expertise, patient diversity, and data excellence.

Strategic tierFounding Data Partner + CustomerTypeStrategic or Co-development Partner
Description

Founding data partner of Clairity's Data Partner Consortium and a real-world implementation site referenced in the company's careers page.

Strategic tierInternational Data PartnerTypeStrategic or Co-development Partner
Description

Member of Clairity's founding Data Partner Consortium, contributing international scale and screening-program data for AI validation.

Strategic tierData PartnerTypeStrategic or Co-development Partner
Description

Member of Clairity's founding Data Partner Consortium, contributing oncology clinical expertise and patient data.

Strategic tierImaging-System Compatibility PartnerTypeTechnology or Integration
Description

Clairity Breast analyzes full-field digital mammograms or directly acquired 2D images from Hologic Lorad Selenia and Selenia Dimensions Mammography Systems (does not analyze synthetic 2D images). Implies technical compatibility/validation with Hologic mammography hardware.

Strategic tierReal-World Deployment SiteTypeImplementation/ SI/ Consulting Partner
Description

Real-world implementation site for Clairity Breast, referenced on the careers page among centers of excellence alongside Beth Israel Deaconess Medical Center and Emory University.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

AI mammography vendor offering ProFound AI for breast cancer detection and risk; competes with Clairity in image-based breast AI deployed inside radiology workflows at U.S. health systems and imaging centers.

TypeDirect peer
Description

Breast health analytics platform focused on breast density, risk modeling, and imaging workflow; targets the same U.S. health system and mammography center customers and overlaps with Clairity on image-based risk and density-driven screening decisions.

TypeDirect peer
Description

Korean AI company with FDA-cleared Lunit INSIGHT MMG for mammography detection and Lunit SCOPE for biomarker prediction; competes with Clairity in image-based breast AI sold to hospitals and screening programs.

TypeDirect peer
Description

Developer of MammoScreen 2.0, an FDA-cleared AI for mammography triage and decision support; directly competes with Clairity in image-based breast AI used by radiologists at point of screening.

TypeDirect peer
Description

Developer of Transpara, an AI decision-support tool for breast imaging that provides lesion detection and risk scoring; comparable to Clairity as an image-only AI deployed inside mammography workflow.

TypeBroad incumbent
Description

Incumbent mammography hardware vendor whose Lorad Selenia/Selenia Dimensions systems are Clairity's current compatibility partner; also developing its own Genius AI Detection and risk applications, making it both a partner and potential competitor.

TypeBroad incumbent
Description

Global imaging OEM and healthcare AI provider whose mammography systems and Edison AI platform offer integrated breast imaging AI; comparable as a broad incumbent that can bundle risk-prediction AI with hardware and enterprise contracts.

TypeBroad incumbent
Description

Mammography hardware vendor with AI-augmented breast imaging (e.g., AI-Rad Companion) deployed across large health system installed bases; overlaps with Clairity on image-based risk and screening workflow.

TypeOthers
Description

Strategic commercial partner integrating MyRisk Hereditary Cancer Test with RiskScore alongside Clairity Breast; adjacent rather than directly competitive, but operates in the same women's health risk-assessment workflow and could evolve into a competitor.

10GRAIL
TypeEmerging player
Description

Multi-cancer early detection company (Galleri test) pursuing blood-based cancer risk and screening; comparable as a precision health risk-prediction platform selling into U.S. health systems and competing for the same preventive-screening dollar.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Clairity

Medical Imaging AI Software / Precision Health Diagnosticsclairity.com

Clairity provides Clairity Breast, an FDA-authorized AI platform that predicts a woman's five-year breast cancer risk directly from a routine screening mammogram. It serves U.S. health systems, academic medical centers, and breast imaging networks via enterprise SaaS, channel integrations, and direct-to-consumer access.

What Clairity does

Clairity, Inc., founded in 2020 and headquartered at 361 Newbury Street, Boston, Massachusetts, develops an AI-powered precision health platform that converts routine screening mammograms into a personalized five-year risk score for breast cancer. Its flagship Software as a Medical Device, Clairity Breast (FDA-authorized under the device name Allix5 via De Novo in May 2025), applies proprietary deep-learning and pixel-level radiomics analysis to full-field digital mammograms and directly acquired 2D images from compatible systems such as Hologic Lorad Selenia/Selenia Dimensions. The model was trained on millions of mammograms with five-year outcome data and validated across more than 122,000 mammograms spanning ten U.S. health systems and European screening programs, achieving a clinical accuracy of AUC 0.72 and identifying a 2–4x higher risk in women missed by traditional density-based methods. Clairity Breast is the first AI mammography risk tool incorporated into the NCCN 2026 Clinical Practice Guidelines for Breast Cancer Screening and Diagnosis, with a 1.7% risk threshold and eligibility starting at age 35.

The platform is delivered to U.S. health systems, academic medical centers, and specialty breast imaging networks through an enterprise SaaS / risk-assessment software licensing model (quote-based, multi-year), embedded inside MagView's Luminary Risk workflow software that reaches 2,500+ U.S. imaging facilities, and combined with Myriad Genetics' MyRisk Hereditary Cancer Test via a co-developed AI + genetic risk offering launched in November 2025. Secondary revenue mechanics include a $40–$60 imaging-center add-on and a $199 direct self-pay option for individual risk scores; insurance coverage remains limited. Named deployments include Beth Israel Deaconess Medical Center (first commercial patient February 23, 2026), Emory University, and Invision Sally Jobe, with a state-by-state U.S. rollout underway (Massachusetts launched; Colorado scheduled April 2026). Clairity is led by founder/CEO Dr. Connie Lehman, with Joe Kiani (founder of Masimo) as Chairman, and has raised approximately $50 million in disclosed funding, most recently a $43 million Series B in November 2025 co-led by ACE Global Equity and Santé Ventures with participation from the Breast Cancer Research Foundation.

Clairity firmographics

Firmographics
Name
Clairity
Legal name
Clairity, Inc.
Website
https://clairity.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
Clairity provides Clairity Breast, an FDA-authorized AI platform that predicts a woman's five-year breast cancer risk directly from a routine screening mammogram. It serves U.S. health systems, academic medical centers, and breast imaging networks via enterprise SaaS, channel integrations, and direct-to-consumer access.
Ownership category
akta.pro rank

Clairity industry classification

Industry
Product category
Medical Imaging AI Software / Precision Health Diagnostics
NAICS
Computer Systems Design and Related Services (54151)
akta.pro industry
PRIMARYHDAAAEAH
Medical Imaging AI
SECONDARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)

Keywords

  • Medical imaging AI
  • Breast cancer risk prediction
  • AI mammography software
  • Precision health diagnostics
  • Software as a medical device

Where Clairity is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Clairity business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Others

Revenue model

  1. Enterprise SaaS / risk-assessment software licensing to health systems and imaging centers: Recurring software access deployed within clinical imaging workflows (e.g., integration with MagView's Luminary Risk used by 2,500+ U.S. facilities and with Myriad Genetics testing workflows). Billed to healthcare providers per the B2B health system contract model.
  2. Per-test / per-mammogram patient access fees (self-pay and imaging-center add-on): Some imaging centers offer the AI analysis as an optional add-on for $40–$60; self-pay option priced at $199. Insurance coverage remains limited, indicating near-term revenue from out-of-pocket per-assessment transactions.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goImaging center add-on (optional AI risk assessment at time of screening)
Unit PricingPay-as-you-goDirect self-pay patient pricing
OtherMulti-year contractEnterprise health system pricing (quote-based)

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Clairity product offering

Product offering

Core offering

Clairity develops and commercializes Clairity Breast (FDA-authorized under the device name Allix5), a Software as a Medical Device (SaMD) that applies deep learning and computer vision to full-field digital mammograms from Hologic Lorad Selenia / Selenia Dimensions systems to output a five-year probability of a woman developing breast cancer, without relying on family history or genetic inputs. The platform is sold primarily as enterprise SaaS/risk-assessment software licensed to U.S. health systems and imaging centers, integrated with MagView's Luminary Risk workflow and Myriad's MyRisk genetic testing, and is also offered as an imaging-center add-on ($40-$60) or self-pay ($199) for individual risk-score access.

Product overview

Clairity, Inc. offers a single unified product, Clairity Breast (FDA-authorized under the device name Allix5), an AI-powered Software as a Medical Device that analyzes routine screening mammograms to produce a personalized 5-year breast cancer risk score. The platform is extended through a workflow integration with MagView's Luminary Risk software that brings Clairity Breast's risk score together with Myriad Genetics' MyRisk Hereditary Cancer Test (with RiskScore) results, so radiologists can act on combined image-based and genetic risk inside their existing breast imaging workflow.

Differentiator

Problem solved

Functional benefit

Brands

  • Clairity Breast: First FDA-authorized AI platform that predicts a woman's five-year future risk of developing breast cancer using only her existing screening mammogram. Authorized under the name Allix5.

Products and services

  • Clairity Breast (FDA-authorized device name: Allix5) Clairity Breast is Clairity's flagship Software as a Medical Device (SaMD) that uses deep learning and computer vision to analyze full-field digital mammograms (or directly acquired 2D images from Hologic Lorad Selenia / Selenia Dimensions systems) and output a personalized five-year probability of a woman developing breast cancer, without relying on family history or genetic inputs. It is FDA De Novo-authorized under the device name Allix5, validated across 120,000+ mammograms from ten U.S. health systems and European screening programs (AUC 0.72), and is sold to U.S. health systems, academic medical centers, and specialty breast imaging networks with deployments at Beth Israel Deaconess Medical Center, Emory University, and Invision Sally Jobe.

Quantifiable outcome

  • 5.9% breast cancer incidence in AI high-risk women vs 1.3% in average-risk (validation studies)
  • +4 more outcomes

Companies that use Clairity

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Clairity technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability3 records

Feature4 records

Clairity partnerships and signals

Strategic signal

Partnerships

14 partnerships are on record, tiered industry alliance participation, flagship launch site, strategic advisory, flagship commercial integration, flagship distribution channel, founding clinical / data partner, founding research partner, data partner, founding data partner + customer, international data partner, imaging-system compatibility partner and real-world deployment site.

  • Patient Safety Movement Foundationindustry alliance participationOthers · 30 March 2026Clairity Inc. signed the Patient Safety Movement Foundation's Open Data Pledge (announced March 30, 2026), joining 90+ organizations committed to making clinical data accessible in secure ways to improve patient safety. The pledge enables appropriate access to data from medical technologies including EHRs, infusion pumps, and physiological monitors, supporting AI-driven predictive algorithms. Joe Kiani (Clairity Chairman) founded the Patient Safety Movement Foundation in 2012.
  • Beth Israel Deaconess Medical Center (BIDMC)flagship launch siteImplementation/ SI/ Consulting Partner · 23 February 2026First medical center in the U.S. to offer Clairity Breast; the first clinical patient received a Clairity Breast cancer risk score on February 23, 2026, marking the clinical debut of the FDA-authorized platform.
  • Clairity Strategic Advisory Boardstrategic advisoryOthers · 2 December 2025Strategic Advisory Board formed December 2, 2025 to support deployment of Clairity's AI-based health prediction tools and the global rollout of its predictive AI technologies at scale. Includes leaders from diagnostics, digital health, and life sciences.
  • Myriad Geneticsflagship commercial integrationStrategic or Co-development Partner · 25 November 2025Jointly developed and launched (Nov 25, 2025) the first integrated AI and genetic risk platform for personalized breast health, combining Clairity Breast (image-based AI) with Myriad's MyRisk Hereditary Cancer Test with RiskScore within MagView's Luminary Risk workflow software. Strategic collaboration also covers U.S. integrated breast cancer risk assessment.
  • MagViewflagship distribution channelStrategic or Co-development Partner · 25 November 2025Co-developed and distributed the first integrated AI + genetic risk platform for personalized breast health. MagView's Luminary Risk workflow software is used by more than 2,500 facilities across the United States, providing broad distribution for Clairity Breast alongside Myriad's MyRisk Hereditary Cancer Test.
  • Massachusetts General Brigham (MGH) / Massachusetts General Hospitalfounding clinical / data partnerStrategic or Co-development PartnerFounding data partner of Clairity's Data Partner Consortium, contributing clinical expertise, patient diversity, and data excellence for AI model development and validation. Founder Dr. Connie Lehman was a Breast Imaging Specialist at MGH (on leave).
  • MIT (Massachusetts Institute of Technology)founding research partnerStrategic or Co-development PartnerFounding data partner and academic research collaborator. Founder Dr. Lehman has a documented research collaboration with MIT that helped fuel Clairity's founding.
  • Stanford Universitydata partnerStrategic or Co-development PartnerMember of Clairity's founding Data Partner Consortium, contributing thought leadership, clinical expertise, and patient diversity.
  • UC Davisdata partnerStrategic or Co-development PartnerMember of Clairity's founding Data Partner Consortium, contributing clinical expertise, patient diversity, and data excellence.
  • Emory Universityfounding data partner + customerStrategic or Co-development PartnerFounding data partner of Clairity's Data Partner Consortium and a real-world implementation site referenced in the company's careers page.
  • RWTH Aachen University (Aachen)international data partnerStrategic or Co-development PartnerMember of Clairity's founding Data Partner Consortium, contributing international scale and screening-program data for AI validation.
  • MD Anderson Cancer Center (MDA)data partnerStrategic or Co-development PartnerMember of Clairity's founding Data Partner Consortium, contributing oncology clinical expertise and patient data.
  • Hologic (Lorad Selenia / Selenia Dimensions)imaging-system compatibility partnerTechnology or IntegrationClairity Breast analyzes full-field digital mammograms or directly acquired 2D images from Hologic Lorad Selenia and Selenia Dimensions Mammography Systems (does not analyze synthetic 2D images). Implies technical compatibility/validation with Hologic mammography hardware.
  • Invision Sally Jobereal-world deployment siteImplementation/ SI/ Consulting PartnerReal-world implementation site for Clairity Breast, referenced on the careers page among centers of excellence alongside Beth Israel Deaconess Medical Center and Emory University.

Scale indicators13 records

Recent moves8 records

Expansion highlights7 records

Clairity competitors and assessment

Company assessment

Direct peers

  • iCAD (DeepHealth): AI mammography vendor offering ProFound AI for breast cancer detection and risk; competes with Clairity in image-based breast AI deployed inside radiology workflows at U.S. health systems and imaging centers.
  • Volpara Health: Breast health analytics platform focused on breast density, risk modeling, and imaging workflow; targets the same U.S. health system and mammography center customers and overlaps with Clairity on image-based risk and density-driven screening decisions.
  • Lunit: Korean AI company with FDA-cleared Lunit INSIGHT MMG for mammography detection and Lunit SCOPE for biomarker prediction; competes with Clairity in image-based breast AI sold to hospitals and screening programs.
  • Therapixel: Developer of MammoScreen 2.0, an FDA-cleared AI for mammography triage and decision support; directly competes with Clairity in image-based breast AI used by radiologists at point of screening.
  • ScreenPoint Medical: Developer of Transpara, an AI decision-support tool for breast imaging that provides lesion detection and risk scoring; comparable to Clairity as an image-only AI deployed inside mammography workflow.

Broad incumbents

  • Hologic: Incumbent mammography hardware vendor whose Lorad Selenia/Selenia Dimensions systems are Clairity's current compatibility partner; also developing its own Genius AI Detection and risk applications, making it both a partner and potential competitor.
  • GE HealthCare: Global imaging OEM and healthcare AI provider whose mammography systems and Edison AI platform offer integrated breast imaging AI; comparable as a broad incumbent that can bundle risk-prediction AI with hardware and enterprise contracts.
  • Siemens Healthineers: Mammography hardware vendor with AI-augmented breast imaging (e.g., AI-Rad Companion) deployed across large health system installed bases; overlaps with Clairity on image-based risk and screening workflow.

Others

  • Myriad Genetics: Strategic commercial partner integrating MyRisk Hereditary Cancer Test with RiskScore alongside Clairity Breast; adjacent rather than directly competitive, but operates in the same women's health risk-assessment workflow and could evolve into a competitor.

Emerging players

  • GRAIL: Multi-cancer early detection company (Galleri test) pursuing blood-based cancer risk and screening; comparable as a precision health risk-prediction platform selling into U.S. health systems and competing for the same preventive-screening dollar.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Clairity social profiles

Digital presence

Clairity compliance and trust

Trust signal

Compliance3 records

Clairity financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Clairity leadership team

Management profile

Number of profiles

Profiles12 records

Clairity funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Clairity M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Clairity

What does Clairity do?

Clairity develops and commercializes Clairity Breast (FDA-authorized under the device name Allix5), a Software as a Medical Device (SaMD) that applies deep learning and computer vision to full-field digital mammograms from Hologic Lorad Selenia / Selenia Dimensions systems to output a five-year probability of a woman developing breast cancer, without relying on family history or genetic inputs. The platform is sold primarily as enterprise SaaS/risk-assessment software licensed to U.S. health systems and imaging centers, integrated with MagView's Luminary Risk workflow and Myriad's MyRisk genetic testing, and is also offered as an imaging-center add-on ($40-$60) or self-pay ($199) for individual risk-score access.

Is Clairity a public or private company?

Clairity is a private company. It is classified as venture growth investor backed and is currently operating.

When was Clairity founded?

Clairity was founded in 2020. It employs 11 to 50 people.

Where is Clairity based?

Clairity is headquartered in Boston, United States, in the North America region.

How does Clairity make money?

Two revenue lines are on record. Enterprise SaaS / risk-assessment software licensing to health systems and imaging centers are the primary driver. The others are per-test / per-mammogram patient access fees (self-pay and imaging-center add-on).

Who are Clairity's main competitors?

Direct peers on record are iCAD (DeepHealth), Volpara Health, Lunit, Therapixel and ScreenPoint Medical. Broad incumbents are Hologic, GE HealthCare and Siemens Healthineers. Myriad Genetics is listed as an others. GRAIL is listed as an emerging player.

Does Clairity have an API?

No public API is recorded for Clairity.

What industry is Clairity in?

Clairity's product category is Medical Imaging AI Software / Precision Health Diagnostics. Its primary akta.pro industry code is HDAAAEAH, Medical Imaging AI, with a secondary code of HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML). Its NAICS code is 54151.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Seattle TimesWomen can now assess their breast cancer risk with the help of AIEverlywell will offer nationwide access to Clairity Breast, an FDA-approved AI tool that predicts a woman's five-year breast cancer risk from a recent mammogram. The test costs $249, is not covered by insurance, and classifies patients as average, intermediate, or high risk. Experts caution that low scores do not eliminate risk and high scores may lead to unnecessary interventions.Inc.Women Have a Powerful New Tool to See Their Risk of Breast Cancer, and It Works With an Existing Mammogram ImageClairity Breast, an AI-powered tool for assessing five-year breast cancer risk, received FDA authorization and is now available nationwide. The tool analyzes mammogram images to output a risk percentage, with scores below 1.7% indicating average risk. It is intended to augment clinical decision-making, not replace it.pharmaphorumEverlywell rolls out Clairity AI for breast cancer in USEverlywell is launching Clairity AI, an FDA-approved tool that assesses five-year breast cancer risk from routine mammograms, across its US network. The partnership expands access to the AI, which detects subtle patterns in breast tissue, and aligns with updated NCCN guidelines. It aims to help women with no family history identify risk early.FinancialContent Business PageEverlywell Brings Clairity’s FDA-Authorized AI Breast Cancer Risk Assessment to Women NationwideEverlywell launched Clairity Breast, an FDA-authorized AI tool that estimates a woman's five-year breast cancer risk from a routine mammogram. The partnership gives U.S. women nationwide access to the assessment, which was validated in over 120,000 mammograms. Updated NCCN guidelines now include AI-based risk assessment as an option for women starting at age 35.The New York TimesWomen Can Now Assess Their Breast Cancer Risk With the Help of A.I.Everlywell will offer Clairity Breast, an FDA-approved AI tool, nationwide starting Thursday to predict a woman's five-year breast cancer risk from a single mammogram. The $249 test is not covered by insurance and provides a percentage score from 0 to 100. Doctors should consider the score alongside other clinical information.FemTech WorldChanges in AI mammogram risk scores help predict future breast cancerResearch involving 54,014 women found that changes in AI-generated mammogram scores can predict breast cancer years before diagnosis, with scores rising steadily among women who later developed the disease but remaining stable among cancer-free women. The increase was detectable up to six years before diagnosis and became steepest in the final two years before diagnosis. The study, led by Professor Constance Lehman of Harvard Medical School and healthcare technology company Clairity, used a validated open-source deep learning model to calculate five-year breast cancer risk scores from mammogram images alone.OncLiveClairity Breast Is Added to NCCN Guidelines for Breast Cancer Screening and DiagnosisThe National Comprehensive Cancer Network updated its 2026 Clinical Practice Guidelines for breast cancer screening and diagnosis to include Clairity Breast, an FDA-authorized AI tool that analyzes mammograms to predict a patient's 5-year breast cancer risk. The updated guidelines introduce a 1.7% risk threshold to identify higher-risk individuals and recommend personalized clinical actions such as supplemental imaging and risk-reduction strategies, expanding risk assessment to patients starting at 35 years of age. This marks the first time an AI-based mammography risk tool has been incorporated into national oncology guidelines, addressing gaps where traditional methods like family history and breast density fail to identify many women at elevated risk.SurvivornetMammogram That Sees the Future: AI Tool Now Officially Part of Breast Cancer Screening Standards and Experts Say Can Help Detect ‘the Likelihood of a Tumor In Five Years’Clairity Breast, an FDA-cleared AI program that analyzes mammograms to predict a woman's five-year breast cancer risk, has been formally incorporated into the National Comprehensive Cancer Network's 2026 Breast Cancer Screening and Diagnosis Guidelines, marking a shift from diagnostic to predictive screening. The NCCN update recommends clinicians take direct action when AI identifies high-risk patients, such as offering supplemental imaging or discussing risk-reduction strategies. Insurance coverage remains limited, with some centers offering AI analysis as an optional add-on for $40–$60 or self-pay at $199, though NCCN inclusion is expected to drive broader adoption.Radiology BusinessNew guidelines recommend AI-based breast cancer risk assessmentsThe NCCN's 2026 guidelines now recommend the use of AI-based breast cancer risk assessments as a primary screening tool, with specific thresholds for additional imaging and lifestyle advice. These assessments are incorporated into routine mammogram procedures starting at age 35. The Clairity Breast platform, an FDA-cleared AI tool, is highlighted for its accuracy in predicting breast cancer risk.Breast Cancer Research FoundationNew NCCN Guidelines Call for AI-Based Mammogram Risk Assessment at 35The NCCN updated its 2026 breast cancer screening guidelines to include AI-based mammogram risk assessment starting at age 35, using a 5-year risk threshold of ≥1.7% to flag increased risk. The guidelines aim to identify women missed by traditional models, with Clairity Breast as the first FDA-authorized platform. Implementation and insurance coverage remain key challenges.